cefotaxime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	546	63527-52-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefotaxime cefotaxime sodium cephotaxime cefotaxime sodium salt	Semisynthetic broad-spectrum cephalosporin. Molecular weight: 455.46 Formula: C16H17N5O7S2 CLOGP: 0.33 LIPINSKI: 1 HAC: 12 HDO: 3 TPSA: 173.51 ALOGS: -3.49 ROTB: 8 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefotaxime
cefotaxime sodium
cephotaxime
cefotaxime sodium salt

Semisynthetic broad-spectrum cephalosporin.

Molecular weight: 455.46
Formula: C16H17N5O7S2
CLOGP: 0.33
LIPINSKI: 1
HAC: 12
HDO: 3
TPSA: 173.51
ALOGS: -3.49
ROTB: 8

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
4	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	30 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	376.38 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.19 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.60 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.20 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	50 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
March 11, 1981	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	235.81	27.61	94	5398	33742	63449788
Toxic epidermal necrolysis	157.89	27.61	65	5427	25269	63458261
Eosinophilia	123.74	27.61	53	5439	22703	63460827
Hepatocellular injury	102.02	27.61	49	5443	27332	63456198
Premature baby	89.24	27.61	41	5451	20694	63462836
Acute generalised exanthematous pustulosis	88.34	27.61	34	5458	11065	63472465
Stevens-Johnson syndrome	87.96	27.61	43	5449	24907	63458623
Rash maculo-papular	83.55	27.61	45	5447	31851	63451679
Septic shock	81.93	27.61	58	5434	66571	63416959
Pyrexia	69.62	27.61	136	5356	470342	63013188
Purpura	63.45	27.61	27	5465	11358	63472172
Multiple organ dysfunction syndrome	61.99	27.61	46	5446	56706	63426824
Patent ductus arteriosus	60.33	27.61	20	5472	4230	63479300
Agranulocytosis	59.02	27.61	33	5459	25101	63458429
Fatigue	55.98	27.61	6	5486	888022	62595508
Foetal exposure during pregnancy	54.17	27.61	34	5458	31928	63451602
Laryngeal stenosis	51.30	27.61	13	5479	1065	63482465
Hydrocephalus	48.55	27.61	18	5474	5282	63478248
Umbilical erythema	48.44	27.61	8	5484	72	63483458
Cholestasis	44.16	27.61	29	5463	29405	63454125
Acute kidney injury	42.30	27.61	79	5413	263336	63220194
Sepsis	41.08	27.61	58	5434	153065	63330465
Necrosis	40.78	27.61	16	5476	5471	63478059
Encephalopathy	39.26	27.61	30	5462	38590	63444940
Subperiosteal abscess	38.31	27.61	5	5487	5	63483525
Cross sensitivity reaction	38.14	27.61	12	5480	2150	63481380
Thrombocytopenia	37.25	27.61	55	5437	151102	63332428
Dermatitis bullous	37.14	27.61	17	5475	8491	63475039
Epidermolysis	36.35	27.61	9	5483	670	63482860
Lactic acidosis	35.14	27.61	28	5464	38259	63445271
Ventricular dysfunction	34.97	27.61	12	5480	2816	63480714
Disseminated intravascular coagulation	34.13	27.61	21	5471	19030	63464500
Dysbiosis	33.78	27.61	9	5483	897	63482633
Arthralgia	33.02	27.61	5	5487	569705	62913825
Petechiae	31.94	27.61	18	5474	13879	63469651
Toxic shock syndrome streptococcal	31.83	27.61	6	5486	121	63483409
Pulmonary necrosis	31.33	27.61	6	5486	132	63483398
Central nervous system necrosis	30.80	27.61	6	5486	145	63483385
Haemophagocytic lymphohistiocytosis	30.65	27.61	16	5476	10611	63472919
Stenotrophomonas infection	30.62	27.61	10	5482	2017	63481513
Clostridium bacteraemia	28.94	27.61	6	5486	200	63483330
Necrotising enterocolitis neonatal	28.68	27.61	6	5486	209	63483321
Oligohydramnios	28.67	27.61	13	5479	6353	63477177
Cyanosis	28.64	27.61	18	5474	16917	63466613
Hepatic failure	28.37	27.61	24	5468	35632	63447898
Respiratory acidosis	28.00	27.61	13	5479	6702	63476828
Toxic skin eruption	27.76	27.61	16	5476	12869	63470661

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	366.90	22.70	160	6457	32852	34917462
Hepatocellular injury	169.24	22.70	83	6534	22128	34928186
Rash maculo-papular	163.74	22.70	88	6529	28363	34921951
Toxic epidermal necrolysis	116.28	22.70	64	6553	21582	34928732
Eosinophilia	97.24	22.70	61	6556	26161	34924153
Clostridium difficile colitis	83.05	22.70	46	6571	15684	34934630
Haemophagocytic lymphohistiocytosis	74.18	22.70	40	6577	12933	34937381
Cholestasis	69.38	22.70	50	6567	26898	34923416
Hepatic cytolysis	67.36	22.70	39	6578	14457	34935857
Agranulocytosis	63.16	22.70	45	6572	23776	34926538
Acute kidney injury	56.54	22.70	155	6462	304833	34645481
Purpura	51.27	22.70	29	6588	10282	34940032
Toxic skin eruption	51.22	22.70	30	6587	11355	34938959
Urethral valves	47.52	22.70	11	6606	275	34950039
Acute generalised exanthematous pustulosis	44.71	22.70	23	6594	6753	34943561
Pyrexia	44.54	22.70	151	6466	332862	34617452
Klebsiella infection	39.74	22.70	23	6594	8508	34941806
Dermatitis bullous	38.60	22.70	21	6596	6901	34943413
Neutropenia	37.59	22.70	88	6529	156690	34793624
Thrombotic microangiopathy	37.54	22.70	24	6593	10606	34939708
Vasculitis necrotising	36.03	22.70	11	6606	809	34949505
Mixed liver injury	35.32	22.70	15	6602	2858	34947456
Drug ineffective	34.74	22.70	174	6443	456577	34493737
Thrombocytopenia	33.49	22.70	84	6533	156163	34794151
Death	31.83	22.70	18	6599	398031	34552283
Fatigue	30.73	22.70	16	6601	370637	34579677
Serratia sepsis	29.27	22.70	6	6611	83	34950231
Off label use	29.20	22.70	156	6461	419368	34530946
Nausea	29.18	22.70	14	6603	339894	34610420
Pancytopenia	29.14	22.70	59	6558	95098	34855216
ADAMTS13 activity decreased	28.88	22.70	6	6611	89	34950225
Systemic candida	28.55	22.70	14	6603	3712	34946602
Red blood cell schistocytes present	28.17	22.70	7	6610	238	34950076
Respiratory gas exchange disorder	28.05	22.70	8	6609	464	34949850
Bicytopenia	27.83	22.70	12	6605	2372	34947942
Septic shock	27.51	22.70	49	6568	71785	34878529
Rash	27.05	22.70	98	6519	222654	34727660
Haematoma muscle	26.80	22.70	10	6607	1358	34948956
Abscess	26.07	22.70	20	6597	11797	34938517
Gamma-glutamyltransferase increased	24.62	22.70	29	6588	29202	34921112
Face oedema	24.34	22.70	19	6598	11497	34938817
CD4 lymphocytes increased	23.71	22.70	6	6611	220	34950094
Serratia infection	23.04	22.70	8	6609	884	34949430
Cross sensitivity reaction	23.02	22.70	9	6608	1388	34948926

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	602.40	23.07	249	10338	63995	79669806
Hepatocellular injury	264.12	23.07	128	10459	47465	79686336
Rash maculo-papular	252.83	23.07	131	10456	55947	79677854
Toxic epidermal necrolysis	250.69	23.07	121	10466	44460	79689341
Eosinophilia	224.91	23.07	113	10474	45232	79688569
Agranulocytosis	126.00	23.07	77	10510	44953	79688848
Purpura	115.73	23.07	55	10532	19472	79714329
Acute generalised exanthematous pustulosis	109.66	23.07	51	10536	17203	79716598
Pyrexia	107.01	23.07	260	10327	678449	79055352
Cholestasis	106.14	23.07	73	10514	52036	79681765
Acute kidney injury	92.64	23.07	209	10378	519195	79214606
Clostridium difficile colitis	92.33	23.07	56	10531	32227	79701574
Hepatic cytolysis	87.84	23.07	51	10536	27100	79706701
Stevens-Johnson syndrome	82.42	23.07	56	10531	39110	79694691
Toxic skin eruption	80.52	23.07	45	10542	22248	79711553
Septic shock	80.32	23.07	90	10497	122711	79611090
Haemophagocytic lymphohistiocytosis	75.94	23.07	43	10544	21794	79712007
Fatigue	73.27	23.07	17	10570	929710	78804091
Dermatitis bullous	72.01	23.07	36	10551	14209	79719592
Thrombocytopenia	67.68	23.07	124	10463	265135	79468666
Neutropenia	57.04	23.07	121	10466	287589	79446212
Pain	55.11	23.07	13	10574	703789	79030012
Cross sensitivity reaction	54.58	23.07	20	10567	3692	79730109
Encephalopathy	53.92	23.07	55	10532	67342	79666459
Multiple organ dysfunction syndrome	51.06	23.07	71	10516	120175	79613626
Mixed liver injury	50.01	23.07	23	10564	7555	79726246
Nausea	48.67	23.07	34	10553	957162	78776639
Pseudomembranous colitis	47.40	23.07	20	10567	5354	79728447
Laryngeal stenosis	45.65	23.07	13	10574	1075	79732726
Thrombotic microangiopathy	42.80	23.07	29	10558	20140	79713661
Arthralgia	40.16	23.07	13	10574	571790	79162011
Hyperbilirubinaemia	39.92	23.07	30	10557	24488	79709313
Red blood cell schistocytes present	38.59	23.07	10	10577	579	79733222
Epidermolysis	38.08	23.07	11	10576	957	79732844
Hydrocephalus	34.97	23.07	19	10568	8881	79724920
Vasculitis necrotising	34.88	23.07	11	10576	1289	79732512
Anaphylactic shock	33.66	23.07	32	10555	35964	79697837
Bicytopenia	33.42	23.07	15	10572	4655	79729146
Klebsiella infection	31.92	23.07	22	10565	15698	79718103
Subperiosteal abscess	28.88	23.07	5	10582	38	79733763
Hepatic failure	28.78	23.07	38	10549	61174	79672627
Pancytopenia	28.59	23.07	66	10521	165679	79568122
Enterococcal infection	27.37	23.07	20	10567	15640	79718161
Ventricular dysfunction	26.89	23.07	14	10573	6009	79727792
ADAMTS13 activity decreased	26.79	23.07	6	10581	186	79733615
Respiratory gas exchange disorder	26.20	23.07	8	10579	843	79732958
Serratia sepsis	26.04	23.07	6	10581	212	79733589
Off label use	25.90	23.07	207	10380	907008	78826793
Rash	24.83	23.07	146	10441	578212	79155589
Brain oedema	24.66	23.07	23	10564	25240	79708561
Central nervous system necrosis	24.27	23.07	6	10581	287	79733514
Gamma-glutamyltransferase increased	24.26	23.07	33	10554	54647	79679154
CD4 lymphocytes increased	24.17	23.07	6	10581	292	79733509
Haematoma muscle	23.96	23.07	10	10577	2605	79731196
Neutrophil count increased	23.52	23.07	24	10563	29372	79704429
Nasopharyngitis	23.49	23.07	3	10584	253878	79479923
HIV associated nephropathy	23.44	23.07	6	10581	331	79733470

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DD01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
ATC	J01DD51	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:88188	allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Streptococcal meningitis	indication	4510004	DOID:11574
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Streptococcal septicemia	indication	29577008
Pneumonia due to Streptococcus	indication	34020007
Neonatal conjunctivitis	indication	34298002	DOID:9699
Pneumonia due to Pseudomonas	indication	41381004
Bacterial arthritis	indication	48245008
Peritonitis	indication	48661000
Lower respiratory tract infection	indication	50417007
Pneumonia due to Escherichia coli	indication	51530003
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Haemophilus influenzae pneumonia	indication	70036007
Bacterial infection due to Serratia	indication	71120004
Septicemia due to Serratia	indication	82091000
Bacterial meningitis	indication	95883001	DOID:9470
Infection of bone	indication	111253001
Female genital tract infection	indication	125585007
Infectious disease of abdomen	indication	128070006
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Meningococcal meningitis	indication	192644005
Escherichia coli meningitis	indication	192655005
Proteus pneumonia	indication	195888009
Sepsis of the newborn	indication	206376005
Neonatal pneumonia	indication	233619008
Neonatal meningitis	indication	276674008
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Bacterial urinary infection	indication	312124009
Meningitis due to Klebsiella mobilis	indication	420585007
Sepsis due to Staphylococcus aureus	indication	448417001
Cesarean Section Infection Prevention	indication
Streptococcal Peritonitis	indication
E. Coli Peritonitis	indication
E. Coli Endometritis	indication
Haemophilus Influenzae Type B Infections	indication
Neonatal Group B Streptococcal Septicemia	indication
Klebsiella Endometritis	indication
Proteus Endometritis	indication
Enterococcus Pelvic Cellulitis	indication
Prevention of Perioperative Infection	indication
Proteus Mirabilis Osteomyelitis	indication
Bacteroides Pelvic Cellulitis	indication
Klebsiella Pelvic Inflammatory Disease	indication
Staphylococcus Endometritis	indication
H. Influenzae Meningitis	indication
Clostridium Pelvic Inflammatory Disease	indication
Haemophilus Parainfluenzae Pneumonia	indication
Bacteroides Pelvic Inflammatory Disease	indication
Staphylococcus Pelvic Inflammatory Disease	indication
Proteus Peritonitis	indication
Clostridium Endometritis	indication
Staphylococcus Epidermidis Urinary Tract Infection	indication
Enterococcus Pelvic Inflammatory Disease	indication
Morganella Morganii Urinary Tract Infection	indication
Fusobacterium Pelvic Inflammatory Disease	indication
Streptococcus Osteomyelitis	indication
Enterococcus Urinary Tract Infection	indication
Clostridium Pelvic Cellulitis	indication
Serratia Urinary Tract Infection	indication
Enterobacter Pneumonia	indication
Enterobacter Pelvic Inflammatory Disease	indication
Bacteroides Endometritis	indication
Providencia Urinary Tract Infection	indication
Citrobacter Urinary Tract Infection	indication
Fusobacterium Endometritis	indication
Proteus Pelvic Inflammatory Disease	indication
Clostridium Peritonitis	indication
Staphylococcus Aureus Urinary Tract Infection	indication
E. Coli Pelvic Inflammatory Disease	indication
E. Coli Pelvic Cellulitis	indication
Enterobacter Endometritis	indication
Pseudomonas Aeruginosa Urinary Tract Infection	indication
Klebsiella Pneumoniae Peritonitis	indication
Enterococcus Endometritis	indication
Pyrexia of unknown origin	off-label use	7520000
Acute gonococcal cervicitis	off-label use	20943002	DOID:10615
Lyme disease	off-label use	23502006	DOID:11729
Acute gonococcal urethritis	off-label use	29864006
Lyme arthritis	off-label use	33937009
Pseudotuberculosis	off-label use	36753006
Gonorrhea of rectum	off-label use	42746002
Lyme carditis	off-label use	77863005
Infection by Yersinia enterocolitica	off-label use	80960004
Ventilator-acquired pneumonia	off-label use	429271009
Disseminated Gonococcal Infection	off-label use
Lyme Disease of the Central Nervous System	off-label use
Acute nephropathy	contraindication	58574008
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.39	acidic
pKa2	13.31	acidic
pKa3	3.1	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Peptidoglycan synthase FtsI	Enzyme	FTSI_ECOLI	INHIBITOR	IC50	6.24	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1A	Enzyme	PBPA_ECOLI	INHIBITOR	IC50	6.51	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1B	Enzyme	PBPB_ECOLI	INHIBITOR	IC50	5.66	WOMBAT-PK	CHEMBL
Penicillin-binding protein 2	Enzyme	PBP2_ECOLI	INHIBITOR	IC50	4.62	WOMBAT-PK	CHEMBL
Beta-lactamase	Enzyme	B2ZTR6_ACIBA		Ki	6.30	CHEMBL
Beta-lactamase	Enzyme	D6NSM8_ACIBA		Ki	5.60	CHEMBL

External reference:

ID	Source
4019663	VUID
N0000147755	NUI
D00919	KEGG_DRUG
64485-93-4	SECONDARY_CAS_RN
203117	RXNORM
C0007554	UMLSCUI
CHEBI:3498	CHEBI
CE3	PDB_CHEM_ID
CHEMBL1010	ChEMBL_ID
CHEMBL1730	ChEMBL_ID
D002439	MESH_DESCRIPTOR_UI
DB00493	DRUGBANK_ID
10893	IUPHAR_LIGAND_ID
4504	INN_ID
N2GI8B1GK7	UNII
10695961	PUBCHEM_CID
42787	MMSL
4378	MMSL
d00008	MMSL
002727	NDDF
004845	NDDF
3334000	SNOMEDCT_US
372704003	SNOMEDCT_US
41722006	SNOMEDCT_US
4018466	VANDF
4019663	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9930	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9931	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9933	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9935	INJECTION	10 g	INTRAVENOUS	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	21586-011	POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	Unapproved drug for use in drug shortage	2 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	21586-011	POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	Unapproved drug for use in drug shortage	2 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	21586-012	POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	Unapproved drug for use in drug shortage	2 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	21586-012	POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	Unapproved drug for use in drug shortage	2 sections
CEFOTAXIME	HUMAN PRESCRIPTION DRUG LABEL	1	55648-947	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	11 sections
CEFOTAXIME	HUMAN PRESCRIPTION DRUG LABEL	1	55648-948	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	11 sections
CEFOTAXIME	HUMAN PRESCRIPTION DRUG LABEL	1	55648-986	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	11 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	64679-947	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	20 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	64679-948	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	20 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	64679-986	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	20 sections